ADHD Advisor, Telehealth Platform

ADHD Advisor is a telehealth platform focused exclusively on ADHD diagnosis and treatment, designed to provide streamlined, specialized care for adults who suspect they have ADHD or who have been previously diagnosed and need ongoing management. The platform operates across 35 states and is built around a distinctive clinical principle: the provider who evaluates you should, where possible, continue as your treatment provider, avoiding the common telehealth pattern of seeing a different clinician at every appointment. The initial evaluation is priced at $150 — $20 collected at booking and the remaining $130 charged after the session. This transparent, below-market pricing for an ADHD evaluation (most in-person neuropsychological assessments cost $1,000–$3,000) makes ADHD Advisor accessible to patients who have been put off by the cost of traditional diagnostic pathways. The evaluation follows a clinical assessment process and results in either a diagnosis or a referral for additional assessment, depending on the complexity of the presentation. A meaningful limitation of ADHD Advisor's current model is its restricted capacity for stimulant prescribing. Outside of California, the platform does not currently offer stimulant medication management — meaning patients who need Adderall, Vyvanse, Ritalin, or other Schedule II stimulants will need to pursue prescribing through a different provider in most states. ADHD Advisor does offer non-stimulant ADHD medications and therapy, making it a viable primary provider for patients who either prefer non-stimulant approaches or have co-occurring conditions where stimulants are contraindicated. The platform does not accept insurance directly but provides a superbill after each appointment that patients can submit for out-of-network reimbursement. HSA and FSA funds are accepted. This structure gives patients the tools to recover a portion of their costs through insurance without the complexity of in-network credentialing on the provider side. ADHD Advisor also offers virtual therapy at $130 per session for patients who want behavioral support alongside evaluation or medication management. For patients seeking the specialization of an ADHD-focused provider with continuity of care and accessible pricing — and who are willing to manage their own insurance submission — it represents a viable alternative to larger generalist platforms. The platform operates across 35 states and is built around a distinctive clinical principle: the provider who evaluates you should, where possible, continue as your treatment provider, avoiding the common telehealth pattern of seeing a different clinician at every appointment. The initial evaluation is priced at $150 — $20 collected at booking and the remaining $130 charged after the session. This transparent, below-market pricing for an ADHD evaluation (most in-person neuropsychological assessments cost $1,000–$3,000) makes ADHD Advisor accessible to patients who have been put off by the cost of traditional diagnostic pathways. The evaluation follows a clinical assessment process and results in either a diagnosis or a referral for additional assessment, depending on the complexity of the presentation. A meaningful limitation of ADHD Advisor's current model is its restricted capacity for stimulant prescribing. Outside of California, the platform does not currently offer stimulant medication management — meaning patients who need Adderall, Vyvanse, Ritalin, or other Schedule II stimulants will need to pursue prescribing through a different provider in most states. ADHD Advisor does offer non-stimulant ADHD medications and therapy, making it a viable primary provider for patients who either prefer non-stimulant approaches or have co-occurring conditions where stimulants are contraindicated. The platform does not accept insurance directly but provides a superbill after each appointment that patients can submit for out-of-network reimbursement. HSA and FSA funds are accepted. This structure gives patients the tools to recover a portion of their costs through insurance without the complexity of in-network credentialing on the provider side. ADHD Advisor also offers virtual therapy at $130 per session for patients who want behavioral support alongside evaluation or medication management. For patients seeking the specialization of an ADHD-focused provider with continuity of care and accessible pricing — and who are willing to manage their own insurance submission — it represents a viable alternative to larger generalist platforms.